TASPOGLUTIDE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C152H232N40O45
Molecular Weight	3339.7095
Optical Activity	UNSPECIFIED
Defined Stereocenters	29 / 29
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC[C@H](C)[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC4=CN=CN4)C(C)O)C(C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC5=CNC6=C5C=CC=C6)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NC(C)(C)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O

InChI

InChIKey=WRGVLTAWMNZWGT-VQSPYGJZSA-N

InChI=1S/C152H232N40O45/c1-20-78(10)119(145(233)168-81(13)125(213)174-105(63-87-66-162-92-39-28-27-38-90(87)92)134(222)176-101(59-75(4)5)135(223)187-117(76(6)7)143(231)173-95(41-30-32-56-154)142(230)192-152(18,19)148(236)184-93(122(157)210)42-33-57-161-150(158)159)189-136(224)103(60-84-34-23-21-24-35-84)177-131(219)99(50-54-115(206)207)172-130(218)94(40-29-31-55-153)170-124(212)80(12)166-123(211)79(11)167-129(217)98(47-51-110(156)199)169-111(200)68-163-127(215)96(48-52-113(202)203)171-132(220)100(58-74(2)3)175-133(221)102(62-86-43-45-89(198)46-44-86)178-139(227)107(70-193)181-141(229)109(72-195)182-144(232)118(77(8)9)188-138(226)106(65-116(208)209)179-140(228)108(71-194)183-147(235)121(83(15)197)190-137(225)104(61-85-36-25-22-26-37-85)180-146(234)120(82(14)196)186-112(201)69-164-128(216)97(49-53-114(204)205)185-149(237)151(16,17)191-126(214)91(155)64-88-67-160-73-165-88/h21-28,34-39,43-46,66-67,73-83,91,93-109,117-121,162,193-198H,20,29-33,40-42,47-65,68-72,153-155H2,1-19H3,(H2,156,199)(H2,157,210)(H,160,165)(H,163,215)(H,164,216)(H,166,211)(H,167,217)(H,168,233)(H,169,200)(H,170,212)(H,171,220)(H,172,218)(H,173,231)(H,174,213)(H,175,221)(H,176,222)(H,177,219)(H,178,227)(H,179,228)(H,180,234)(H,181,229)(H,182,232)(H,183,235)(H,184,236)(H,185,237)(H,186,201)(H,187,223)(H,188,226)(H,189,224)(H,190,225)(H,191,214)(H,192,230)(H,202,203)(H,204,205)(H,206,207)(H,208,209)(H4,158,159,161)/t78-,79-,80-,81-,82+,83+,91-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,117-,118-,119-,120-,121-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C152H232N40O45
Molecular Weight	3339.7095
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	29 / 29
E/Z Centers	23
Optical Activity	UNSPECIFIED

Description
Sources: https://www.medicalnewstoday.com/articles/200893.php | https://clinicaltrials.gov/ct2/show/NCT00909597 | https://www.ncbi.nlm.nih.gov/pubmed/30968335

Taspoglutide is a glucagon-like peptide-1 agonist was studied in phase III clinical trials for the treatment patients with type 2 diabetes. However, in September 2010 Roche halted Phase III clinical trials due to gastrointestinal intolerability and serious hypersensitivity reactions experienced by some trial participants.

Originator

Approval Year

PubMed

Title	Date	PubMed
Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study.	2009 Jul	19366970
Utilization of model-based meta-analysis to delineate the net efficacy of taspoglutide from the response of placebo in clinical trials.	2015 Jul	26106272
Cardiovascular safety of the glucagon-like peptide-1 receptor agonist taspoglutide in people with type 2 diabetes: an individual participant data meta-analysis of randomized controlled trials.	2015 May	25656522
Subcutaneous Bioavailability of Taspoglutide at 3 Different Injection Sites in Healthy Overweight/Obese Subjects.	2015 Nov 1	26412802
Effect of varying degrees of renal impairment on the pharmacokinetics and tolerability of taspoglutide.	2017 Apr	27981717
Assessment of Drug-Drug Interactions between Taspoglutide, a Glucagon-Like Peptide-1 Agonist, and Drugs Commonly Used in Type 2 Diabetes Mellitus: Results of Five Phase I Trials.	2019 Sep	30968335

Sample Use Guides

In Vivo Use Guide

taspoglutide 10mg sc weekly

Route of Administration: Other

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:00:23 UTC 2023` Edited by `admin` on `Fri Dec 15 16:00:23 UTC 2023`
Record UNII	2PHK27IP3B
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TASPOGLUTIDE

Official Name

English

RO5073031

Code

English

R-1583

Code

English

[8-(2-Amino-2-methylpropanoic acid),35-(2-amino-2-methylpropanoic acid)]human glucagon-like peptide 1 (GLP-1)-(7-36)-peptidamide

Common Name

English

7-36-GLUCAGON-LIKE PEPTIDE I (HUMAN), 8-(2-METHYLALANINE)-35-(2-METHYLALANINE)-36-L-ARGININAMIDE-

Common Name

English

BIM51077

Code

English

taspoglutide [INN]

Common Name

English

R1583

Code

English

TASPOGLUTIDE [USAN]

Common Name

English

Taspoglutide [WHO-DD]

Common Name

English

TASPOGLUTIDE [MI]

Common Name

English

RO-5073031

Code

English

BIM-51077

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C98085